International developments in the care of familial hypercholesterolemia: Where now and where to next?

Journal of Atherosclerosis and Thrombosis

Volumn 23, Issue 5, 2016, Pages 505-519

  Pang, Jing ^a   Lansberg, Peter J ^b,c   Watts, Gerald F ^a,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Center for Translational Molecular Medicine Translational Research Infrastructure (CTMM TraIT)   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Cost effectiveness; Education; Familial hypercholesterolemia; Heart disease; Models of care; Prevention; Registries; Risk; Screening; Treatment

Indexed keywords

LOW DENSITY LIPOPROTEIN; LIPOPROTEIN;

APHERESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EARLY DIAGNOSIS; EDUCATION PROGRAM; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC SCREENING; HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; OBESITY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING; TRAINING; BLOOD; CHEMISTRY; COST BENEFIT ANALYSIS; FAMILY HEALTH; GENETICS; HOMOZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; INTERNATIONAL COOPERATION; PRACTICE GUIDELINE; PREVALENCE; PROCEDURES; PSYCHOLOGY; REGISTER; SELF HELP;

ATHEROSCLEROSIS; BLOOD COMPONENT REMOVAL; COST-BENEFIT ANALYSIS; FAMILY HEALTH; GUIDELINES AS TOPIC; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INTERNATIONALITY; LIPOPROTEINS; LIPOPROTEINS, LDL; PREVALENCE; QUALITY OF LIFE; REGISTRIES; RISK FACTORS; SELF-HELP GROUPS;

EID: 84964700521     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.34108     Document Type: Review

References (125)

1. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK and Livingston M: Integrated Guidance on the Care of Familial Hypercholesterolaemia from the International FH Foundation. Int J Cardiol, 2014; 171: 309-325
2. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ and Defesche JC: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Consensus Statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-3490
3. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL and Ziajka PE: Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol, 2011; 5: 133-140
4. Benn M, Watts GF, Tybjaerg-Hansen A and Nordestgaard BG: Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. J Clin Endocrinol Metab, 2012; 97: 3956-3964
5. Shi Z, Yuan B, Zhao D, Taylor AW, Lin J and Watts GF: Familial hypercholesterolemia in China: Prevalence and evidence of underdetection and undertreatment in a community population. Int J Cardiol, 2014; 174: 834-836
6. Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJG, Roeters van Lennep JE, Stalenhoef AFH, Wiegman A, de Graaf J, Fouchier SW, Kastelein JJP and Hovingh GK: Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J, 2014; ehu058
7. Watts GF, Shaw JE, Pang J, Magliano DJ, Jennings GLR and Carrington MJ: Prevalence and treatment of familial hypercholesterolemia in Australian communities. Int J Cardiol, 2015; 185: 69-71
8. Pang J, Martin AC, Mori TA, Beilin LJ and Watts GF: Prevalence of familial hypercholesterolaemia in adolescents: potential value of universal screening? The Journal of Pediatrics, 2015; 170: 315-316
9. Miller PE, Martin SS, Toth PP, Santos RD, Blaha MJ, Nasir K, Virani SS, Post WS, Blumenthal RS and Jones SR: Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). J Clin Lipidol, 2015; 9: 676-683
10. Santos RD, Gagliardi ACM, Xavier HT, Casella Filho A, Araujo DB, Casena FYR.J. A: Brazilian Guidelines to Familial Hypercholesterolaemia (FH). Arq Bras Car diol, 2012; 99: 1-28
11. Genest J, Hegele RA, Bergeron J, Brophy J, Carpentier A, Couture P, Davignon J, Dufour R, Frohlich J, Gaudet D, Gupta M, Krisnamoorthy P, Mancini J, McCrindle B, Raggi P, Ruel I and St-Pierre J: Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia. Can J Cardiol, 2014; 30: 1471-1481
12. Farnier M, Bruckert E, Boileau C and Krempf M: Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: Guidelines from the New French Society of Atherosclerosis (NSFA). Presse medicale [Epub ahead of print], 2013;
13. Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K and Wakatsuki A: Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb, 2012; 19: 1043-1060
14. National Institute for Health and Clinical Excellence and The National Collaborating Centre for Primary Care: NICE Clinical Guideline 71: Identification and management of familial hypercholesterolaemia. 2008;
15. Hopkins PN, Toth PP, Ballantyne CM and Rader DJ: Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol, 2011; 5: S9-S17
16. Nordestgaard B, Chapman M, Humphries S, Ginsberg H, Masana L, Descamps O, Wiklund O, Hegele R, Raal F, Defesche J, Wiegman A, Santos R, Watts G, Parhofer K, Kees Hovingh G, Kovanen P, Boileau C, Averna M, Boren J, Bruckert E, Catapano A, Kuivenhoven J, Pajukanta P, Ray K, Stalenhoef A, Stroes E, Taskinen M, Tybjaerg-Hansen A and P ftEASC: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-3490
17. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AFH, Steinhagen-Thiessen E, Stroes ES, Taskinen M-R, Tybjærg-Hansen A and Wiklund O: Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J, 2015; 36: 2425-2437
18. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, O'Brien R, Bishop W, George P, Barter PJ, Bates T, Burnett JR, Coakley J, Davidson P, Emery J, Martin A, Farid W, Freeman L, Geelhoed E, Juniper A, Kidd A, Kostner K, Krass I, Livingston M, Maxwell S, O'Leary P, Owaimrin A, Redgrave TG, Reid N, Southwell L, Suthers G, Tonkin A, Towler S and Trent R: Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 2011; 12: 221-263
19. Marang-van de Mheen PJ, ten Asbroek AHA, Bonneux L, Bonsel GJ and Klazinga NS: Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in the Netherlands. Eur Heart J, 2002; 23: 1922-1930
20. Ademi Z, Watts GF, Pang J, Sijbrands EJG, van Bockxmeer FM, O'Leary P, Geelhoed E and Liew D: Cascade Screening Based on Genetic Testing is Cost-effective: Evidence for the Implementation of Models of Care for Familial Hypercholesterolaemia. J Clin Lipidol, 2014; 8: 390-400
21. Pears R, Griffin M, Watson M, Wheeler R, Hilder D, Meeson B, Bacon S and Byrne CD: The reduced cost of providing a nationally recognised service for familial hypercholesterolaemia. Open Heart, 2014; 1: e000015
22. Goldstein JL, Hobbs HH and Brown MS: The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill Information Services Company, New York, 2001
23. Austin MA, Hutter CM, Zimmern RL and Humphries SE: Genetic causes of monogenic heterozygous familial hypercholesterolaemia: A HuGE prevalence review. Am J Epidemiol, 2004; 160: 407-420
24. Ashavaid T, Altaf A and Nair K: Molecular basis of familial hypercholesterolemia: an Indian experience. Indian Journal of Clinical Biochemistry, 2000; 15: 11-19
25. Setia N, Verma I, Khan B and Arora A: Premature coronary artery disease and familial hypercholesterolemia: need for early diagnosis and cascade screening in the Indian population. Cardiology research and practice, 2011; 2012
26. De Backer G, Besseling J, Chapman J, Hovingh GK, JJP K, Ray K, Reiner Z, Wood D and De Bacquer D: Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV. Atherosclerosis, 2015; 241: 169-175
27. Pang J, Poulter EB, Bell DA, Bates TR, Jefferson V-L, Hillis GS, Schultz CJ and Watts GF: Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. J Clin Lipidol, 2015; 9: 703-708
28. Civeira F: Guidelines for the diagnosis and management of heterozygous familial hypercholesterolaemia. Atherosclerosis, 2004; 173: 55-68
29. Daniels SR, Gidding SS and de Ferranti SD: Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol, 2011; 5: S30-S37
30. Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, De Beaufort C, De Waele K, Scheen A, Rietzschel E, Mangano A, Panier JP, Ducobu J, Langlois M, Balligand JL, Legat P, Blaton V, Muls E, Van Gaal L, Sokal E, Rooman R, Carpentier Y, De Backer G and Heller FR: Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis, 2011; 218: 272-280
31. Kusters DM, de Beaufort C, Widhalm K, Guardamagna O, Bratina N, Ose L and Wiegman A: Paediatric screen ing for hypercholesterolaemia in Europe. Arch Dis Child, 2012; 97: 272-276
32. Martin AC, Coakley J, Forbes DA, Sullivan DR and Watts GF: Familial hypercholesterolaemia in children and adolescents: A new paediatric model of care. J Paediatr Child Health, 2012; 49: E263-E272
33. Klančar G, Grošelj U, Kovač J, Bratanič N, Bratina N, Podkrajšek KT and Battelino T: Universal screening for familial hypercholesterolemia in children. J Am Coll Cardiol, 2015; 66: 1250-1257
34. Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG, Scheerder RLJM and Kastelein JJP: Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet, 2001; 357: 165-168
35. Haralambos K, Whatley SD, Edwards R, Gingell R, Townsend D, Ashfield-Watt P, Lansberg P, Datta DBN and McDowell IFW: Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis, 2015; 240: 190-196
36. Jannes CE, Santos RD, de Souza Silva PR, Turolla L, Gagliardi ACM, Marsiglia JDC, Chacra AP, Miname MH, Rocha VZ, Filho WS, Krieger JE and Pereira AC: Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects. Atherosclerosis, 2015; 238: 101-107
37. Bell DA, Pang J, Burrows S, Bates TR, van Bockxmeer FM, Hooper AJ, O'Leary P, Burnett JR and Watts GF: Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience. Atherosclerosis, 2015; 239: 93-100
38. Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, Kastelein JJP, Mata P, Raal FJ, Santos RD, Soran H, Watts GF, Abifadel M, Aguilar-Salinas CA, Akram A, Alnouri F, Alonso R, Al-Rasadi K, Banach M, Bogsrud MP, Bourbon M, Bruckert E, Car J, Corral P, Descamps O, Dieplinger H, Durst R, Freiberger T, Gaspar IM, Genest J, Harada-Shiba M, Jiang L, Kayikcioglu M, Lam CSP, Latkovskis G, Laufs U, Liberopoulos E, Nilsson L, Nordestgaard BG, O'Donoghue JM, Sahebkar A, Schunkert H, Shehab A, Stoll M, Su T-C, Susekov A, Widén E, Catapano AL and Ray KK: Familial hypercholesterolaemia: A global call to arms. Atherosclerosis, 2015; 243: 257-259
39. Hu M, Lan W, Lam CWK, Mak YT, Pang CP and Tomlinson B: Heterozygous familial hypercholesterolemia in Hong Kong Chinese. Study of 252 cases. Int J Cardiol, 2013; 167: 762-767
40. Tai E, Ming Loh L, Sethi SK, Koay ES, Teng Lim Y and Tan C-E: MEDPED comes to Singapore. Atherosclerosis, 2001; 154: 252
41. Shin DG, Han SM, Kim DI, Rhee M-Y, Lee B-K, Ahn YK, Cho BR, Woo J-T, Hur S-H, Jeong J-O, Jang Y, Lee JH and Lee S-H: Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease-A study supported by the Korean Society of Lipidology and Atherosclerosis. Atherosclerosis, 2015; 243: 53-58
42. Chen CX and Hay JW: Cost-effectiveness analysis of alternative screening and treatment strategies for hetero-zygous familial hypercholesterolemia in the United States. Int J Cardiol, 2015; 181: 417-424
43. Weng SF, Kai J, Andrew Neil H, Humphries SE and Qureshi N: Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). Atherosclerosis, 2015; 238: 336-343
44. Kirke AB, Barbour RA, Burrows S, Bell DA, Vickery AW, Emery J and Watts GF: Systematic Detection of Familial Hypercholesterolaemia in Primary Health Care: A Community Based Prospective Study of Three Methods. Heart Lung Circ, 2015; 24: 250-256
45. Gray J, Jaiyeola A, Whiting M, Modell M and Wierzbicki AS: Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart, 2008; 94: 754-758
46. Bell DA, Edwards G, Hooper AJ, McMahon J, van Bockxmeer FM, Watts GF and Burnett JR: The potential role of an expert computer system to augment the opportunistic detection of individuals with familial hypercholesterolaemia from a community laboratory. Clin Chim Acta, 2015; 448: 18-21
47. Wald DS, Bestwick JP and Wald NJ: Child-parent screening for familial hypercholesterolaemia: Screening strategy based on a meta-analysis. Br Med J, 2007; 335: 599-603
48. Henneman L, McBride C, Cornel M, Duquette D and Qureshi N: Screening for Familial Hypercholesterolemia in Children: What Can We Learn From Adult Screening Programs? Healthcare, 2015; 3: 1018
49. Morris JK, Wald DS and Wald NJ: The evaluation of cascade testing for familial hypercholesterolemia. American Journal of Medical Genetics Part A, 2011; 158: 78-84
50. Hill JS, Hayden M, Frohlich J and Pritchard P: Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol, 1991; 11: 290-297
51. Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y and Hunt SC: Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. The American Journal of Cardiology, 2001; 87: 547-553
52. De Sauvage Nolting PRW, Defesche JC, Buirma RJA, Hutten BA, Lansberg PJ and Kastelein JJP: Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med, 2003; 253: 161-168
53. Jansen ACM, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, Roeters van Lennep HWO, Sijbrands EJG and Kastelein JJP: The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med, 2004; 256: 482-490
54. Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S, Matsuzawa Y, Ishibashi S, Shionoiri F, Yamada N and Kita T: Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan. J Atheroscler Thromb, 2004; 11: 146-151
55. Neil HAW, Seagroatt V, Betteridge DJ, Cooper MP, Durrington PN, Miller JP, Seed M, Naoumova RP, Thompson GR, Huxley R and Humphries SE: Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart, 2004; 90: 1431-1437
56. Nenseter MS, Lindvig HW, Ueland T, Langslet G, Ose L, Holven KB and Retterstøl K: Lipoprotein (a) levels in coronary heart disease-susceptible and-resistant patients with familial hypercholesterolemia. Atherosclerosis, 2011; 216: 426-432
57. Alonso R, Andres E, Mata N, Fuentes-Jiménez F, Badimón L, López-Miranda J, Padró T, Muñiz O, Díaz-Díaz JL and Mauri M: Lipoprotein (a) levels in Familial Hipercholesterolaemia: an important predictor for cardiovascular disease independent of the type of LDL-receptor mutation. J Am Coll Cardiol, 2014; 63: 1982-1989
58. Allard MD, Saeedi R, Yousefi M and Frohlich J: Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Diabetes, 2014; 13: 65
59. Chan DC, Pang J, Hooper AJ, Burnett JR, Bell DA, Bates TR, van Bockxmeer FM and Watts GF: Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol, 2015; 201: 633-638
60. Neefjes LA, Ten Kate G-JR, Rossi A, Galema-Boers AJ, Langendonk JG, Weustink AC, Moelker A, Nieman K, Mollet NR and Krestin GP: CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia. Heart, 2011; 97: 1151-1157
61. Neefjes LA, ten Kate G-JR, Alexia R, Nieman K, Galema-Boers AJ, Langendonk JG, Weustink AC, Mollet NR, Sijbrands EJ, Krestin GP and de Feyter PJ: Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis, 2011; 219: 721-727
62. Miname MH, Ribeiro Ii MS, Filho JP, Avila LF, Bortolotto LA, Martinez LRC, Rochitte CE and Santos RD: Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis, 2010; 213: 486-491
63. Shipman KE, Higginson EJ, Haddon AL, Wong MY and Labib MZ: The use of CT coronary calcium score in asymptomatic patients with familial hypercholesterolaemia. British Journal of Diabetes & Vascular Disease, 2015; http: //dx.doi.org/10.15277/bjdvd.12015.15039
64. Patel J, Al Rifai M, Blaha MJ, Budoff MJ, Post WS, Polak JF, Bluemke DA, Scheuner MT, Kronmal RA, Blumenthal RS, Nasir K and McEvoy JW: Coronary Artery Calcium Improves Risk Assessment in Adults With a Family History of Premature Coronary Heart Disease: Results From Multiethnic Study of Atherosclerosis. Circulation: Cardiovascular Imaging, 2015; 8: e003186
65. Tada H, Kawashiri M-a, Okada H, Teramoto R, Konno T, Yoshimuta T, Sakata K, Nohara A, Inazu A, Kobayashi J, Mabuchi H, Yamagishi M and Hayashi K: Assessment of Coronary Atherosclerosis in Patients With Familial Hypercholesterolemia by Coronary Computed Tomography Angiography. The American Journal of Cardiology, 2015; 115: 724-729
66. Sijbrands EJ, Nieman K and Budoff MJ: Cardiac computed tomography imaging in familial hypercholesterolemia: implications for therapy and clinical trials. Curr Opin Lipidol, 2015; 26: 586-592
67. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ and Stalenhoef AF: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet, 2001; 357: 577-581
68. de Jongh S, Lilien MR, op't Roodt J, Stroes ESG, Bakker HD and Kastelein JJP: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol, 2002; 40: 2117-2121
69. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJP and Sijbrands EJG: Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J, 2008; 337: a2423
70. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE and on behalf of the Simon Broome Familial Hyperlipidaemia Register Group: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J, 2008; 29: 2625-2633
71. Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y, Yamashita T, Miyamoto Y, Yamamoto A, Tomoike H and Yokoyama S: Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2010; 17: 667-674
72. Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ and Durrington P: ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J, 2011; 32: 1769-1818
73. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC, Sorlie P, Stone NJ and Wilson PWF: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014; 129: S49-S73
74. Lamaida N, Capuano E, Pinto L, Capuano E, Capuano R and Capuano V: The safety of statins in children. Acta Paediatr, 2013; 102: 857-862
75. Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJ, Wiegman A and Hutten BA: Ten-Year Follow-up After Initiation of Statin Therapy in Children With Familial Hypercholesterolemia. JAMA, 2014; 312: 1055-1057
76. Kastelein JJP, Kusters M, Caceres M, Coll M, Cuffie C, Gagné C, Jacobson M, Kwiterovich P, Lee R and Lowe R: Efficacy and safety of ezetimibe monotherapy in children six to ten years of age with heterozygous familial or non-familial hypercholesterolaemia. J Am Coll Cardiol, 2013; 61: 10
77. van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagne C, Shi G, Veltri E, Avis HJ and Kastelein JJP: Efficacy and Safety of Coadministration of Ezetimibe and Simvastatin in Adolescents With Heterozygous Familial Hypercholesterolemia. J Am Coll Cardiol, 2008; 52: 1421-1429
78. Vuorio A, Doherty KF, Humphries SE, Kuoppala J and Kovanen PT: Statin treatment of children with familial hypercholesterolemia-trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis, 2013; 226: 315-320
79. Gouni-Berthold I and Berthold HK: Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Atherosclerosis Supplements, 2015; 18: 28-34
80. Mullard A: PCSK9 inhibitors are go. Nature Reviews Drug Discovery, 2015; 14: 593-594
81. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS and Steinhagen-Thiessen E: Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J, 2014; ehu274
82. Baum SJ, Sijbrands EJG, Mata P and Watts GF: The Doctor's Dilemma: Challenges in the Diagnosis and Care of 'Homozygous Familial Hypercholesterolemia'. J Clin Lipidol, 2014; 8: 542-549
83. Besseling J, Kindt I, Hof M, Kastelein JJP, Hutten BA and Hovingh GK: Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14,000 mutation carriers. Atherosclerosis, 2014; 233: 219-223
84. Bell DA, Garton-Smith J, Vickery A, Kirke AB, Pang J, Bates TR and Watts GF: Familial Hypercholesterolaemia in Primary Care: Knowledge and Practices among General Practitioners in Western Australia. Heart Lung Circ, 2014; 23: 309-313
85. Foody JM: Familial Hypercholesterolemia: An Underrecognized but Significant Concern in Cardiology Practice. Clin Cardiol, 2013; 37: 119-125
86. Pang J, Sullivan DR, Harada-Shiba M, Ding PY, Selvey S, Ali S and Watts GF: Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: A pilot study. J Clin Lipidol, 2015; 9: 42-48
87. Withycombe B, Winden JC, Hassanyn R, Duell PB and Ito MK: The extent of familial hypercholesterolemia instruction in US schools and colleges of medicine, pharmacy, and osteopathic medicine. J Clin Lipidol, 2015; 9: 281-288
88. Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra K, Black HR, Blumenthal RS, Davidson MH, Fazio SB, Ferdinand KC, Fine LJ, Fonseca V, Franklin BA, McBride PE, Mensah GA, Merli GJ, O'Gara PT, Thompson PD and Underberg JA: ACCF/ AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. J Am Coll Cardiol, 2009; 54: 1336-1363
89. Hammond E, Watts GF, Rubinstein Y, Farid W, Livingston M, Knowles JW, Lochmüller H, Bellgard M and Dawkins HJS: Role of international registries in enhancing the care of familial hypercholesterolaemia. Int J Evid Based Healthc, 2013; 11: 134-139
90. Haralambos K: "PASS Clinical" Software for Familial Hypercholesterolaemia (FH): Evaluation report including 3 month clinical pilot. 2009; Available from: www. heartuk.org.uk/FHToolkit/
91. Betteridge D: Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis, 1999; 142: 105-112
92. Mata N, Alonso R, Badimón L, Padró T, Fuentes F, Muñiz O, Perez-Jiménez F, López-Miranda J, Díaz JL, Vidal JI, Barba A, Piedecausa M, Sanchez JF, Irigoyen L, Guallar E, Ordovas JM and Mata P: Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis, 2011; 10: 94
93. Wong S, Taraboanta C, Francis G, Ignaszewski A and Frohlich J: The British Columbia Familial Hypercholesterolemia Registry. BC Medical Journal, 2013; 55: 326-300
94. O'Brien EC, Roe MT, Fraulo ES, Peterson ED, Ballantyne CM, Genest J, Gidding SS, Hammond E, Hemphill LC, Hudgins LC, Kindt I, Moriarty PM, Ross J, Underberg JA, Watson K, Pickhardt D, Rader DJ, Wilemon K and Knowles JW: Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. Am Heart J, 2014; 167: 342-349.e317
95. Béliard S, Millier A and Bruckert É: A French cohort of patients with familial hypercholesterolemia. 2015
96. Bamimore MA, Zaid A, Banerjee Y, Al-Sarraf A, Abifadel M, Seidah NG, Al-Waili K, Al-Rasadi K and Awan Z: Familial hypercholesterolemia mutations in the Middle Eastern and North African region: A need for a national registry. J Clin Lipidol, 2015; 9: 187-194
97. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, McCrindle B, Raal F, Rader D, Santos RD, Lopes-Virella M, Watts GF and Wierzbicki AS: The Agenda for Familial Hypercholesterolemia-A Scientific Statement From the American Heart Association. Circulation, 2015; 132: DOI: 10.1161/ CIR.0000000000000297
98. Hardcastle SJ, Legge E, Laundy CS, Egan SJ, French R, Watts GF and Hagger MS: Patients' Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment. International Journal of Behavioral Medicine, 2015; 22: 92-100
99. Agard A, Bolmsjo I, Hermeren G and Wahlstom J: Familial hypercholesterolemia: Ethical, practical and psychological problems from the perspectives of patients. Patient Educ Couns, 2005; 57: 162-167
100. Tonstad S: Familial hypercholesterolaemia: a pilot study of parents' and children's concerns. Acta Paediatr, 1996; 85: 1307-1313
101. de Jongh S, Kerckhoffs MC, Grootenhuis MA, Bakker HD, Heymans HSA and Last BF: Quality of life, anxiety and concerns among statin-treated children with familial hypercholesterolaemia and their parents. Acta Paediatr, 2003; 92: 1096-1101
102. Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, Brekke M, Retterstøl K, Arnesen K-E and Ose L: Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol, 2012; 6: 331-339
103. Page MM, Bell DA, Hooper AJ, Watts GF and Burnett DJR: Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Practice & Research Clinical Endocrinology & Metabolism 2013; 28: 387-403
104. The EAS FH Studies Collaboration (FHSC). 2015; 2015: http://www.eas-society.org/?page=fhsc
105. Screening Project for Familial Hypercholesterolemia in Central, Southern and Eastern Europe. 2015; 2015
106. Datta BN, McDowell IF and Rees A: Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol, 2010; 21: 366-371
107. Vickery AW, Bell D, Garton-Smith J, Kirke AB, Pang J and Watts GF: Optimising the Detection and Management of Familial Hypercholesterolaemia: Central Role of Primary Care and its Integration with Specialist Services. Heart Lung Circ, 2014; 23: 1158-1164
108. Pedersen KMV, Humphries SE, Roughton M and Besford JS: The National Audit of the Management of Familial Hypercholesterolaemia 2010: Full report. 2010
109. Aarden E, Van Hoyweghen I and Horstman K: The paradox of public health genomics: Definition and diagnosis of familial hypercholesterolaemia in three European countries. Scand J Public Health, 2011; 39: 634-639
110. Watts GF, Juniper A, van Bockxmeer F, Ademi Z, Liew D and O'Leary P: Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. Int J Evid Based Healthc, 2012; 10: 211-221
111. Bellgard MI, Render L, Radochonski M and Hunter A: Second generation registry framework. Source Code Biol Med, 2014; 9: 1-6
112. Benn M, Watts GF, Tybjaerg-Hansen A and Nordestgaard BG: Corrigendum. The Journal of Clinical Endocrinology & Metabolism, 2014; 99: 4758-4759
113. Patterson D and Slack J: Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. The Lancet, 1972; 299: 393-399
114. Goldstein JL, Hazzard WR, Schrott HG, Bierman EL and Motulsky AG: Hyperlipidemia in coronary heart disease I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest, 1973; 52: 1533
115. Goldstein J, Schrott H, Hazzard W, Bierman E and Motulsky A: Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest, 1973; 52: 1544-1568
116. Nikkilä E and Aro A: Family study of serum lipids and lipoproteins in coronary heart-disease. The Lancet, 1973; 301: 954-959
117. Koivisto UM, Hamalainen L, Taskinen MR, Kettunen K and Kontula K: Prevalence of familial hypercholesterolemia among young North Karelian patients with coronary heart disease: A study based on diagnosis by polymerase chain reaction. J Lipid Res, 1993; 34: 269-277
118. Gaudet D, Vohl M-C, Julien P, Tremblay G, Perron P, Gagné C, Bergeron J, Moorjani S and Després J-P: Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians. The American Journal of Cardiology, 1998; 82: 299-305
119. Dorsch MF, Lawrance RA, Durham NP and Hall AS: Familial hypercholesterolaemia is underdiagnosed after AMI. Br Med J, 2001; 322: 111
120. Bates TR, Burnett JR, van Bockxmeer FM, Hamilton S, Arnolda L and Watts GF: Detection of familial hypercholesterolaemia: A major treatment gap in preventative cardiology. Heart Lung Circ, 2008; 17: 411-413
121. Rallidis LS, Lekakis J, Panagiotakos D, Fountoulaki K, Komporozos C, Apostolou T and Kremastinos DT: Long-term prognostic factors of young patients (≤ 35 years) having acute myocardial infarction: the detrimental role of continuation of smoking. Eur J Cardiovasc Prev Rehabil, 2008; 15: 567-571
122. Wiesbauer F, Blessberger H, Azar D, Goliasch G, Wagner O, Gerhold L, Huber K, Widhalm K, Abdolvahab F, Sodeck G, Maurer G and Schillinger M: Familial-combined hyperlipidaemia in very young myocardial infarction survivors (≤ 40 years of age). Eur Heart J, 2009; 30: 1073-1079
123. Yudi M, Omera L, McCubbery N, Dick S, Jayasinghe R and Hamilton-Craig I: Suboptimal consideration and management of potential familial hypercholesterolaemia in patients with suspected premature coronary artery disease. Singapore Med J, 2012; 53: 174-178
124. Wald DS, Bangash FA and Bestwick JP: Prevalence of DNA-confirmed Familial Hypercholesterolaemia in young patients with myocardial infarction. European journal of internal medicine, 2015; 26: 127-130
125. Nanchen D, Gencer B, Auer R, Räber L, Stefanini GG, Klingenberg R, Schmied CM, Cornuz J, Muller O, Vogt P, Jüni P, Matter CM, Windecker S, Lüscher TF, Mach F and Rodondi N: Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J, 2015; 36: 2438-2445